disease awareness campaign
Takeda’s zasocitinib shows high rates of skin clearance in phase 3 psoriasis studies
Globally, an estimated 64 million people have psoriasis, with about 80-90% of those having plaque psoriasis
J&J’s Tremfya approved by FDA for children with plaque psoriasis and psoriatic arthritis
The drug is the first IL-23 inhibitor approved for children from the age of six
North East and North Cumbria NHS rolls out digital health platform to combat chronic kidney disease, affecting 1 in 10 UK adults
In a significant step towards tackling one of the UK’s most underdiagnosed conditions, North East and North Cumbria Integrated Care Board (ICB) has adopted the Healthinote digital health platform, providing...
Bridging the gap in personalised digital support: My Stroke Companion
To empower stroke survivors to engage with their care, Cognitant, in partnership with University College London Hospitals (UCLH), identified a need for a new digital health companion that can support...
Kidney Research UK invests in Healthinote patient education platform which could support >15m people with long term health conditions
Kidney Research UK, the leading charity dedicated to kidney health, has made a significant investment in Cognitant Group Ltd, a leading provider of digital education and support tools to improve...
Health literacy & the creation of shared decision aids for patients with cancer
In this blog, Gini Melesi, Head of Transformation, East of England Cancer Alliance, & Diane Whitney, Head of Brachytherapy Physics, Cambridge University Hospitals NHS Foundation Trust, explore the relationship between...
FDA approves new presentation of Celltrion’s SteQeyma for paediatric psoriasis
The Stelara biosimilar now offers all dosage forms and strengths of its reference product
LEO and Reig Jofre partner to improve access to psoriasis therapy in Europe
Approximately 125 million people worldwide are affected by some form of the inflammatory condition
Bristol Myers Squibb shares five-year results for Sotyktu in plaque psoriasis
Plaque psoriasis affects up to 90% of patients with the immune-mediated disease
Bristol Myers Squibb’s Sotyktu shows promise in phase 3 psoriatic arthritis trials
The immune-mediated disease affects approximately 30% of people living with psoriasis
AbbVie to expand immunology pipeline with $200m Nimble Therapeutics acquisition
The deal includes an IL23R inhibitor in preclinical development for psoriasis and inflammatory bowel disease
Johnson & Johnson’s Tremfya shows promise in ‘special site’ plaque psoriasis
The immune-mediated disease affects more than 125 million people worldwide